61 results on '"Aringer, Martin"'
Search Results
2. Faculty Opinions recommendation of Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.
3. Faculty Opinions recommendation of Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial.
4. Faculty Opinions recommendation of Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma.
5. Faculty Opinions recommendation of Scleroderma renal crisis and renal involvement in systemic sclerosis.
6. Faculty Opinions recommendation of UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis.
7. Faculty Opinions recommendation of Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.
8. Faculty Opinions recommendation of Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials.
9. Faculty Opinions recommendation of Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.
10. Faculty Opinions recommendation of Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
11. Faculty Opinions recommendation of Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features.
12. Faculty Opinions recommendation of Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
13. Faculty Opinions recommendation of Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.
14. Faculty Opinions recommendation of Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.
15. Faculty Opinions recommendation of Mycophenolate mofetil following cyclophosphamide in worsening systemic sclerosis-associated interstitial lung disease
16. Faculty Opinions recommendation of Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series.
17. Faculty Opinions recommendation of Involvement of functional autoantibodies against vascular receptors in systemic sclerosis.
18. Faculty Opinions recommendation of Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
19. Faculty Opinions recommendation of Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
20. Faculty Opinions recommendation of Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
21. Faculty Opinions recommendation of Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH).
22. Faculty Opinions recommendation of Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.
23. Faculty Opinions recommendation of Analysis of immune reconstitution after autologous CD34+ stem/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells.
24. Faculty Opinions recommendation of Selexipag for the treatment of pulmonary arterial hypertension.
25. Faculty Opinions recommendation of Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
26. Faculty Opinions recommendation of Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis.
27. Faculty Opinions recommendation of Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis.
28. Faculty Opinions recommendation of Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study.
29. Faculty Opinions recommendation of Early systemic sclerosis: analysis of the disease course in patients with marker autoantibody and/or capillaroscopic positivity.
30. Faculty Opinions recommendation of Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
31. Faculty Opinions recommendation of Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
32. Faculty Opinions recommendation of Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria.
33. Faculty Opinions recommendation of Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
34. Faculty Opinions recommendation of Baricitinib in Patients with Refractory Rheumatoid Arthritis.
35. Faculty Opinions recommendation of Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab.
36. Faculty Opinions recommendation of Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.
37. Faculty Opinions recommendation of Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort.
38. Faculty Opinions recommendation of Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.
39. Faculty Opinions recommendation of Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction.
40. Faculty Opinions recommendation of Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.
41. Faculty Opinions recommendation of Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
42. Faculty Opinions recommendation of A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis.
43. Faculty Opinions recommendation of An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
44. Faculty Opinions recommendation of The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.
45. Faculty Opinions recommendation of Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial.
46. Faculty Opinions recommendation of Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
47. Faculty Opinions recommendation of Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.
48. Faculty Opinions recommendation of Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis.
49. Faculty Opinions recommendation of Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial.
50. Faculty Opinions recommendation of The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.